

PATENT

Docket No. GC527- US
SN 09/060,872

☐ Urgent
☐ Confidential
☐ Action Required
☐ Reply Requested
☐ For Your Info.

FAX COVER SHEET

TO: Art Unit 1644

LOCATION: USPTO

Fax No.: (703) 872-9307 (After Final Facsimile No.) GROUP 1600

FROM: Carol See for Kamrin T. MacKnight

LOCATION: GENENCOR INTERNATIONAL, INC.
Legal Department
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-7549
Fax: 650-845-6504

FAX RECEIVED

APR 10 2003

OFFICIAL

DATE: April 9, 2003

NUMBER OF PAGES TO FOLLOW: 11 SENT BY: cas

Re: Serial No. 09/060,872, Attorney Docket No. GC527- US

Attachments: Transmittal (1 page) in duplicate, Amendment and Response to
Final Office Action and Advisory Action (9 pages).

The original of this facsimile will be sent to you via:

☐ Regular Mail ☐ Overnight Mail ☐ Hand Delivery ☒ Will Not Be Sent

☒ Please initial acknowledgment of receipt by return facsimile _____

NOTE: The information contained in this facsimile message is confidential and may be subject to attorney-client privilege and is intended only for the use of the above named individual(s). If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone(650/846-7517) and return the original transmission to us by mail.

GC527-US-faxcvf-pto

Received from < 650 845 6504 > at 4/9/03 12:52:56 PM [Eastern Daylight Time]

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, After Final Facsimile No. (703) 872-9307, Box AF, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: April 9, 2003By: 

Carol A. See

PATENT
Docket No. GC527

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application:

David A. Estell et al.

Serial No.: 09/060,872

Filed: April 15, 1998

For: Mutant Proteins Having Lower Allergenic
Response in Humans and Methods for
Constructing, Identifying and Producing Such
Proteins

Group Art Unit: 1644

Examiner: Saunders, David A.

TRANSMITTAL LETTER

Box AF
Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Final Office Action dated January 7, 2003 and the Advisory Action mailed March 26, 2003, enclosed please find the following document:
Amendment and Response to Final Office Action and Advisory Action.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC527). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: April 9, 2003


Kamrin T. MacKnight

Registration No. 38,230

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-5838
Fax: 650-845-6504

GC527 AF-AA T-OFFACT

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, After Final Facsimile No. (703) 872-9307, Box AF, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: April 9, 2003

By:

Carol A. See

#42/H
Gorga
4-11-03
N.E.PATENT
Docket No. GC527

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application:)	
)	
David A. Estell et al.)	Group Art Unit: 1644
)	
Serial No.: 09/060,872)	Examiner: Saunders, David A.
)	
Filed: April 15, 1998)	
)	
For: Mutant Proteins Having Lower Allergenic)	
Response in Humans and Methods for)	
Constructing, Identifying and Producing Such)	
Proteins)	

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
MAILED JANUARY 7, 2003 AND ADVISORY ACTION MAILED MARCH 26, 2003

Box AF
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Final Office Action dated January 7, 2003, and the Advisory Action mailed March 26, 2003, Applicants respectfully request reconsideration of the above-identified application in view of the following remarks.

A clean version of the rewritten, added, and/or cancelled claims with instructions for entry pursuant to 37 C.F.R. §1.121 (c)(1)(i) is included beginning on page 2 of this communication. A marked-up version of rewritten, added, and/or cancelled claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) is attached as Appendix I. A clean version of the entire set of pending claims pursuant to 37 C.F.R. §1.121 (c)(3) as they would appear following entry of this amendment is attached as Appendix II. None of the amendments

GC527 Respm to Final and Advisory